Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Androfin, Crinormin, Finastad, Finasterid, Prezepa, Propecia, Proscar; Belgium: Finasteride, Proscar; Bulgaria: Finanorm, Hyplafin, Penester, Prezepa, Propecia, Proscar; Cyprus: Impruve, Propecia, Proscar; Czech Republic: Androfin, Apo-Finas, Duromeran, Edufil, Finajelf, Finanorm, Finard, Finasterid, Finasteride, Finex, Finpros, Gefin, Ibition, Lekoprost, Mostrafin, Penester, Propecia, Radicut; Denmark: Finasterid, Propecia, Proscar; Estonia: Androfin, Finasterid, Finasteride, Finpros, Penester, Propecia, Ulgafen; Finland: Finasterid, Gefina, Propecia, Proscar, Tifisterid; France: Chibro-Proscar, Finasteride, Propecia; Germany: Crinormin, Deltafin, Fina-TEVA, Finafrank, Finafried, FinaHAIR, Finamed, Finapart, Finapecia, Finascar, Finasterid, Finis, Finural, Propecia, Proscar, Prosmin; Greece: Alsteride, Finar, Finasteride, Finazil, Fisterid, Profin, Profinosa, Prohype, Propecia, Proplasia, Proscar, Prostafin; Hungary: Andofin, Finanorm, Finasted, Finasterid, Finasteride, Finpros, Hyplafin, Proscar, Prosterid; Ireland: Finasteride, Finocard, Fintex, Fintrid, Profal, Proscar; Italy: Asterid, Finasteride, Finastid, Finerid, Folians, Genaprost, Pilus, Propecia, Proscar, Prostide, Ridestin; Latvia: Androfin, Finasterid, Finasteride, Finster, Penester, Proscar, Prostarinol, Ulgafen; Lithuania: Androfin, Finasterid, Finasteride, Finster, Penester, Ulgafen; Luxembourg: Proscar; Malta: Finasteride, Propecia, Proscar; Netherlands: Finasteride, Propecia, Proscar; Poland: Ambulase, Androstatin, Antiprost, Apo-Fina, Aprost, FinaGen, Finamef, Finaran, Finaride, Finaster, Finasterid, Finasteride, Finasteridum, Finasteryd, Fincar, Finpros, Fintral, Finxta, Hyplafin, Lifin, Penester, Propecia, Proscar, Reduprost, Symasteride, Ulgafen, Zasterid; Portugal: Binprós, Finasterida, Finox, Growancer, Propecia, Proscar, Prostacide, Prostafin, Zidoril; Romania: Enyde, Finanorm, Finasterid, Finasterida, Finasteride, Mostrafin, Propecia, Proscar, Taredox; Slovakia: Finajelf, Finanorm, Finasterid, Finpros, Penester; Slovenia: Finpros, Hyplafyn, Mostrafin, Propecia, Prostide; Spain: Finasterida, Litace, Propecia, Proscar; Sweden: Capipro, Erastafin, Finasterid, Finasteride, Finementin, Finoplasa, Finpros, Profina, Propecia, Proscar, Prosmin, Ridafinatabs, Teridisol; UK: Propecia, Proscar.

North America

Canada: Propecia, Proscar; USA: Propecia, Proscar.

Latin America

Argentina: Andropel, Avertex, Daric, Finasteride, Finasterin, Finterac, Flutiamik, Folcres, HPB Panalab, IVIX Fin, Nasteril, Propecia, Proscar, Prosmin, Prostanil, Prostanovag, Prostene, Q-prost, Renacidin, Sutrico, Tealep, Tresaride, Tricofarma, Urofin, Urototal, Vetiprost; Brazil: Alfasyn, Capyla, Fendical, Finalop, Finastec, Finasterida, Finastil, Flaxin, Nasterid, Pracap, Pro Hair, Pronasteron-Finasteride, Propecia, Proscar, Prostide; Mexico: Fhilterin, Propeshia, Proscar, Riterid-Z, Vanorid.


Japan: Propecia.

Drug combinations

Finasteride and Tamsulosin


Finasteride: C~23~H~36~N~2~O~2~. Mw: 372.54. (1) 4-Azaandrost-1-ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5α,17β)-; (2) N-tert-butyl-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide. CAS-98319-26-7 (1989).

Pharmacologic Category

5-α-Reductase Inhibitors. (ATC-Code: D11AX10; G04CB01).

Mechanism of action

Finasteride is a competitive inhibitor of both tissue and hepatic 5-α-reductase. This results in inhibition of conversion of testosterone to dihydrotestosterone, and markedly suppresses serum dihydrotestosterone levels.

Therapeutic use

Finasteride is used to reduce prostatic size, urinary obstruction and associated manifestations (e.g. urinary hesitancy and/or urgency, nocturia), risk of acute urinary retention, and of need for surgery (including transurethral resection of prostate and prostatectomy) in symptomatic benign prostatic hyperplasia.

Pregnancy and lactiation implications

Abnormalities of external male genitalia reported in animal studies. Pregnant women should avoid contact with crushed or broken tablets. Not indicated for use in women.

Unlabeled use

Adjuvant monotherapy after radical prostatectomy in treatment of prostatic cancer. Female hirsutism.


Hypersensitivity to finasteride or any component of the formulation. Pregnancy. Not for use in children.

Warnings and precautions

Hazardous agent. Pregnant women or women trying to conceive should not handle the product. Use with caution in hepatic impairment. Other urological diseases including cancer should be ruled out before initiating. Duration of therapy minimum 6 months. Reduces prostate specific antigen (PSA) by 50%.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart